Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Bortezomib and lenalidomide as first-line treatment for older patients with myeloma

Peter Barth • 13 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Cyclophosphamide Dexamethasone Lenalidomide

Peter Barth, MD, of Brown University, Providence, RI, discusses the benefit found in triplet induction therapy compared to that of various double induction therapies in elderly multiple myeloma patients in a retrospective study. This interview was recorded at the International Myeloma Workshop (IMW) 2019, in Boston, MA.

More from Peter Barth

Determining the prognostic significance of upfront radiation therapy in MM
0:58
Determining the prognostic significance of upfront radiation therapy in MM
Peter Barth • 14 Sep 2019

Related Videos

Favorable tolerability and early outcomes with full dose lenalidomide in older adults with NDMM
1:37
Favorable tolerability and early outcomes with full dose lenalidomide in older adults with NDMM
Peter Barth • 8 Dec 2025
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
2:35
A novel remote monitoring system to support outpatient administration of bispecific T-cell engagers
Peter Barth • 15 Dec 2025
Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
2:53
Impact of race and social deprivation on clinical outcomes in newly diagnosed multiple myeloma
Peter Barth • 7 Dec 2025
The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
2:15
The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
Peter Barth • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals